ma.31 trial: taxane with lapatinib or trastuzumab in first-line metastatic breast cancer
Published 11 years ago • 478 plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
7:30
aphinity trial in her2 breast cancer
-
5:01
neoadjuvant lapatinib in her2 early breast cancer
-
3:15
neratinib for metastatic breast cancer
-
13:18
role of lapatinib in her2-positive breast cancer
-
4:29
aphinity trial: adjuvant pertuzumab and trastuzumab
-
3:27
ecco14: clinical trials of new breast cancer drug lapatinib.
-
1:33
rimawi: lapatinib trastuzumab with endocrine therapy
-
10:40
inb03 and lapatinib reverses resistance to trastuzumab in her2 breat cancer in pre-clinical models.
-
3:03
phase ii trial of patritumab deruxtecan in metastatic breast cancer
-
9:35
neratinib in her2 breast cancer
-
1:40
phase 2/3 trial of maintenance lapatinib for her1/2-positive metastatic bladder cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
4:34
the best sequence of anti-her2 therapy in metastatic breast cancer
-
5:51
the aphinity trial
-
28:25
metastatic triple-negative breast cancer ongoing trials
-
1:39
treatment for her2 metastatic breast cancer
-
2:06
dr. jahanzeb on the aphinity and extenet trials in breast cancer
-
1:28
dr. dawar on challenges with neratinib in metastatic her2 breast cancer